Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $5.89 and traded as high as $6.13. Abeona Therapeutics shares last traded at $5.89, with a volume of 1,209,450 shares trading hands.
Analyst Ratings Changes
Several brokerages have recently weighed in on ABEO. Stifel Nicolaus decreased their price target on Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Alliance Global Partners reissued a "buy" rating on shares of Abeona Therapeutics in a research note on Thursday, May 15th. Oppenheimer assumed coverage on Abeona Therapeutics in a research note on Monday, June 2nd. They issued an "outperform" rating and a $19.00 price target for the company. Wall Street Zen downgraded Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 15th. Finally, HC Wainwright lifted their target price on Abeona Therapeutics from $15.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $19.25.
Get Our Latest Stock Analysis on ABEO
Abeona Therapeutics Stock Performance
The company has a market cap of $301.33 million, a PE ratio of -4.64 and a beta of 1.54. The company has a quick ratio of 4.90, a current ratio of 4.90 and a debt-to-equity ratio of 0.27. The company has a 50-day moving average of $5.89 and a 200-day moving average of $5.58.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.11. As a group, analysts anticipate that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current year.
Insiders Place Their Bets
In other news, SVP Brendan M. O'malley sold 10,470 shares of the company's stock in a transaction on Friday, June 6th. The stock was sold at an average price of $6.76, for a total transaction of $70,777.20. Following the transaction, the senior vice president now owns 378,245 shares of the company's stock, valued at $2,556,936.20. This represents a 2.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Vishwas Seshadri sold 25,000 shares of the company's stock in a transaction on Monday, March 31st. The shares were sold at an average price of $4.78, for a total value of $119,500.00. Following the transaction, the chief executive officer now directly owns 1,355,322 shares in the company, valued at $6,478,439.16. This represents a 1.81% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 113,941 shares of company stock valued at $711,341. Insiders own 6.90% of the company's stock.
Hedge Funds Weigh In On Abeona Therapeutics
Large investors have recently modified their holdings of the business. Twinbeech Capital LP bought a new position in Abeona Therapeutics in the 4th quarter worth about $58,000. Squarepoint Ops LLC bought a new position in Abeona Therapeutics in the 4th quarter worth about $67,000. Cannon Global Investment Management LLC bought a new position in Abeona Therapeutics in the 1st quarter worth about $67,000. Oxford Asset Management LLP bought a new position in Abeona Therapeutics in the 4th quarter worth about $118,000. Finally, Balyasny Asset Management L.P. bought a new position in Abeona Therapeutics in the 4th quarter worth about $190,000. Hedge funds and other institutional investors own 80.56% of the company's stock.
Abeona Therapeutics Company Profile
(
Get Free Report)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Abeona Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.
While Abeona Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
